Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431363 · ClinicalTrials.gov registry record
Medical Cannabis During Chemoradiation for Head and Neck Cancer
A clinical trial, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- 30
- Enrollment target
NCT03431363: Completed study, sponsored by Albert Einstein College of Medicine.
NCT03431363 is a clinical trial that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03431363 has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The primary purpose of the study is to observe the adherence and health seeking behavior of patients with Head and Neck cancer (HNC) certified to obtain medically certified cannabis as part of their supportive care regimen undergoing treatment with definitive or adjuvant concurrent chemoradiation (CRT).
Primary Outcome
The primary endpoint of aim 1 is a determination of the number of patients registering for medically certified cannabis as assessed as the number (frequency) as well as proportion of patients registering on New York State Medical Marijuana website. Patients' adherence percentage will be presented along with Clopper-Pearson exact 95% confidence interval.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2026-01-14 |
What the finished NCT03431363 record still lists
NCT03431363 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03431363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03431363 about?
NCT03431363 is a clinical study titled "Medical Cannabis During Chemoradiation for Head and Neck Cancer". The primary purpose of the study is to observe the adherence and health seeking behavior of patients with Head and Neck cancer (HNC) certified to obtain medically certified cannabis as part of their supportive care regimen undergoing treatment with definitive or adjuvant concurrent chemoradiation (C...
What is the current status of trial NCT03431363?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-05-18. Estimated completion is 2026-01-14.
Who is sponsoring clinical trial NCT03431363?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI